Ipamorelin + Sermorelin for Men: What Research in Men Has Looked At

A 1992 National Institute on Aging study gave ten healthy men aged about 68 GHRH(1-29) twice daily for 14 days; at the higher dose, growth hormone and IGF-1 rose to levels not significantly different from men in their twenties, with the pulsatile pattern intact. Body composition was not measured.

A 1997 Johns Hopkins trial in Metabolism gave eleven healthy men aged 64 to 76 single nightly injections of 2 mg for six weeks. Nocturnal growth hormone rose, two of six strength measures improved, and IGF-1, weight, body composition, glucose and lipids did not change. The authors concluded that single nightly doses are less effective than multiple daily doses.

A 1997 UC San Diego trial in the Journal of Clinical Endocrinology and Metabolism gave nine men and ten women aged 55 to 71 a closely related analogue nightly for 16 weeks.

What it shows. Men had more of a body-composition and metabolic response than women in this one trial.

What it does not show. That the changes are large, lasting or repeatable. Nine men is a very small group, self-ratings are self-reports, and no trial has looked at sermorelin in men under about 55.

A 1999 dose-escalation study in Pharmaceutical Research gave healthy male volunteers intravenous ipamorelin at five dose levels. It reported a half-life of about two hours and a single episode of growth hormone release at every dose, peaking at about 40 minutes and falling to negligible levels afterwards. It measured growth hormone only: not sleep, body composition, strength, recovery or testosterone. It did not use the subcutaneous route prescribed today. The selectivity that gave ipamorelin its reputation, releasing growth hormone without raising ACTH or cortisol, was shown in rats and pigs in 1998 and is inferred in men rather than measured.

No study has tested this pairing. The human evidence for combining a GHRH signal with a ghrelin-receptor signal comes from a 1995 paper in Clinical Endocrinology that gave eight healthy men GHRH(1-29) and GHRP-2, a different ghrelin-receptor peptide, separately and together. The combination produced the largest response, roughly the sum of the two, with no synergy. Whether ipamorelin and sermorelin behave the same way at nightly subcutaneous doses has not been tested.

In healthy men sampled around the clock, daily growth hormone secretion fell by roughly 14 percent per decade, and each extra unit of body mass index cut it by a further 6 percent or so (Journal of Clinical Endocrinology and Metabolism, 1991). A 2000 JAMA analysis of 149 healthy men found deep slow-wave sleep and growth hormone secretion declining together from early adulthood. Those studies describe a decline. They do not show that restoring a pulse changes how a man sleeps, recovers or ages.

Both peptides act on growth hormone release, a separate pituitary system from the one that drives testosterone. Neither raises testosterone or replaces it. Low testosterone on two morning blood draws with symptoms is hypogonadism, treated with testosterone under its own monitoring. Pepti does not prescribe or sell testosterone. See peptides for testosterone.

Men on testosterone replacement often ask about a growth-hormone-axis peptide. There is no trial of this pairing, or any compounded secretagogue, alongside testosterone replacement. The trials that combined recombinant growth hormone with testosterone in older men flagged glucose: in a 2002 JAMA trial, diabetes or glucose intolerance occurred in 18 growth-hormone-treated men against 7 not receiving it. Those trials supplied the hormone from outside, which is not what this vial does, but they are why glucose belongs in the conversation. List your testosterone on the intake. More in can you take peptides with testosterone.

Growth hormone reduces insulin sensitivity, and the secretagogue literature names rising glucose as its recurring concern. In the sermorelin trials fasting glucose was unchanged. Diabetes or impaired glucose tolerance needs discussing at intake, and thirst or frequent urination is worth reporting.

Both peptides raise your own growth hormone and, with it, IGF-1. No study has shown that either causes cancer. A 2004 systematic review in the Lancet reported that higher circulating IGF-1 in the general population was associated with a higher risk of prostate cancer, among others; that is an observational association about natural levels, not evidence about a monitored medication. A personal history of cancer, including prostate cancer, goes on the intake in full. See can peptides cause cancer.

Snoring, gasping at night or heavy daytime sleepiness are reasons for a sleep assessment first; neither peptide treats a breathing cause of poor sleep. Evening alcohol, caffeine after midday and an inconsistent wake time degrade deep sleep faster than any vial improves it. Peptides for men over 40 sets out what a physician looks at first.

No human fertility outcome data exists for either component. Neither supplies a hormone that switches off the testes' own signal, but no trial has measured sperm on them. Say so on the intake if you are trying to conceive. See do peptides affect fertility.

The 2026 WADA Prohibited List names both sermorelin and ipamorelin under S2.2.4, prohibited at all times. A prescription does not change that. See is Ipamorelin + Sermorelin banned in sports.